Investor FAQs
Lumos Pharma was incorporated in Delaware on June 4, 1999 as NewLink Genetics Corporation and changed its name to Lumos Pharma on March 18, 2020.
Lumos Pharma’s corporate headquarters is in Austin, Texas.
Lumos Pharma’s fiscal year-end is December 31.
Lumos Pharma’s independent registered public accounting firm is KMPG LLP.
Lumos Pharma’s common stock is traded under the ticker symbol LUMO on the NASDAQ Global Select Stock Market.
You can purchase shares of Lumos Pharma stock through a stockbroker. Lumos Pharma does not have a direct stock purchase program.
Lumos Pharma does not pay a cash or stock dividend on its common stock. Lumos Pharma anticipates that it will retain all available funds and any future earnings for use in the operation of its business and does not anticipate paying a dividend in the foreseeable future.
The CUSIP number for Lumos Pharma’s common stock is 55028X109.
Lumos Pharma’s transfer agent is Computershare Shareowner Services LLC. Shareholders can contact them through the following channels:
By phone:
Toll-free (888) 213-0965
By regular mail:
PO Box 30170
College Station, TX 77842
By overnight delivery:
211 Quality Circle
Suite 210
College Station, TX 77845
Shareholders can access their account online here.
A copy of our Annual Report or other periodic reports to the Securities and Exchange Commission is available without charge upon written request to:
Corporate Secretary
Lumos Pharma, Inc.
2503 South Loop Drive
Suite 5100
Ames, IA 50010
The names of Lumos Pharma’s Board of Directors can be found here.
The names of Lumos Pharma’s management team can be found here.
To contact Lumos Pharma Investor Relations, please send an email to ir@lumos-pharma.com.
To contact Lumos Pharma Media Relations, please send an email to ir@lumos-pharma.com.
You can find Lumos Pharma’s press releases here.
You can find information on Lumos Pharma’s R&D programs here.